Contributions
Abstract: PB2238
Type: Publication Only
Background
Bortezomib (BTZ) represents an important progress in the treatment of multiple myeloma（MM）.BTZ combined with other agents is becoming a standard care.The combination of BTZ with dexamethasone previously shown the superior to VAD.
Aims
To observe the efficacy and safety of bortezomib，cyclophosphamide，dexamethasone（VCD) versus bortezomib，dexamethasone（VD) regimens in treatment of patients with newly diagnosed multiple myeloma (NDMM).
Methods
To retrospective analysis of the 73 patients with NDMM from January 2013 to January 2016 in Department of Hematology，Dayi Hospital.they were divided into VCD arm and VD arm, The outcomes of two different regimens were analyzed, including response and adverse events
Results
he overall response rate was 80.5%(33/41)with VCD arm and 78.1%(25/32)with VD arm,with no statistically significant difierences(P=0.804）.However,complete response was 36.6%(15/41) with VCD arm and 15.6%(5/32)with VD arm,and differences were statistically significant (P=0.046) ,The median progression free survival(PFS) was 27 and 24 months in VCD arm and VD arm,The median overall survival(OS) was 35 and 33 months in VCD arm and VD arm,with no statistically significant difierences(P>0.05).Peripheral neuritis (PN),thrombocytopenia,diarrhea and constipation are the most common adverse events in two groups.There was no statistically significant difference between the two groups (P>0.05).Most adverse events were in grade 1 and 2.
Conclusion
Both VCD and VD regimens are effective induction chemotherapy choices for NDMM. VCD is preferable to VD terms of achieving complete remission.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Cyclophosphamide, Dexamethasone, Multiple Myeloma, Velcade
Abstract: PB2238
Type: Publication Only
Background
Bortezomib (BTZ) represents an important progress in the treatment of multiple myeloma（MM）.BTZ combined with other agents is becoming a standard care.The combination of BTZ with dexamethasone previously shown the superior to VAD.
Aims
To observe the efficacy and safety of bortezomib，cyclophosphamide，dexamethasone（VCD) versus bortezomib，dexamethasone（VD) regimens in treatment of patients with newly diagnosed multiple myeloma (NDMM).
Methods
To retrospective analysis of the 73 patients with NDMM from January 2013 to January 2016 in Department of Hematology，Dayi Hospital.they were divided into VCD arm and VD arm, The outcomes of two different regimens were analyzed, including response and adverse events
Results
he overall response rate was 80.5%(33/41)with VCD arm and 78.1%(25/32)with VD arm,with no statistically significant difierences(P=0.804）.However,complete response was 36.6%(15/41) with VCD arm and 15.6%(5/32)with VD arm,and differences were statistically significant (P=0.046) ,The median progression free survival(PFS) was 27 and 24 months in VCD arm and VD arm,The median overall survival(OS) was 35 and 33 months in VCD arm and VD arm,with no statistically significant difierences(P>0.05).Peripheral neuritis (PN),thrombocytopenia,diarrhea and constipation are the most common adverse events in two groups.There was no statistically significant difference between the two groups (P>0.05).Most adverse events were in grade 1 and 2.
Conclusion
Both VCD and VD regimens are effective induction chemotherapy choices for NDMM. VCD is preferable to VD terms of achieving complete remission.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Cyclophosphamide, Dexamethasone, Multiple Myeloma, Velcade